This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Janssen PharmaceuticalCompanies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).
He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.
While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.
At the same time, lots of people with experience at multinational pharmaceuticalcompanies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceuticalcompanies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%
AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. AMR is already the third leading cause of death worldwide, causing around 1.27
In the last decade, immunotherapies that treat cancers using the patient’s immune system to recognise, attack and kill malignant cells have reached the market. Cancer is one of the leading causes of death globally, and improving therapeutic strategies in haematology and oncology remains a priority in healthcare.
Traditionally, cancer patients are treated using “one size fits all” interventions like chemotherapy, radiotherapy and surgery. To deliver these unique therapies to patients, pharmaceuticalcompanies must partner with a wide range of specialized third parties including laboratories, manufacturers, shipping and storing providers.
Shots: Drug patent expiry is when a patent granted to a pharmaceuticalcompany for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years.
Hence, they are commonly used in the treatment of cancer, as part of the chemotherapy regime. Besides cancer, they are also increasingly being used for other medical conditions such as rheumatoid arthritis, multiple sclerosis and other auto immune disorders. They can also inhibit or prevent the function of cells.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content